Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Yixin Pharmaceutical Co., Ltd. (Sinopharm Yixin for short), a holding subsidiary of the company, received the “Notice of Termination of Drug Registration Application” issued by the China Drug Administration (NDRA), agreeing to Sinopharm Yixin to withdraw the registration application for cyclophosphamide injections.

According to reports, cyclophosphamide injections are mainly suitable for malignant lymphoma, multiple myeloma, leukemia, breast cancer, etc. Sinopharm submitted the marketing registration application for this product to the State Drug Administration in September 2023 and was accepted. Due to the need to further improve research work, the State Drug Administration recently agreed to withdraw the registration application for this product and terminate the registration process. The withdrawal of the cyclophosphamide injection registration application will not have a significant impact on the company's current business performance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.